LONDON, April 23 (Reuters) - AstraZeneca Plc (AZN.L: Quote, Profile , Research) has agreed to buy U.S. biotechnology company MedImmune Inc. (MEDI.O: Quote, Profile , Research) for more than $15 billion in the biggest transaction since the creation of the Anglo-Swedish drugs group in 1999.
